hotspot -WSS

hotspot

author：knowledge 2025-09-28 00:53:23 - browse：88215

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Better Therapeutics data on benefit with GLP

focus

WSS

CDC says it’s too soon to assess risk posed by Covid subvariant

PBMs are inflating the cost of generic drugs. They must be reined in

How the drug

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Listen: Vivek Ramaswamy's star turn & leaky drug data

Bernie Sanders bashes nonprofit hospitals over their tax breaks

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Anesthesiologist group: stop taking Ozempic before surgery

Peter Marks talks Operation Warp Speed for Rare Diseases

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bernie Sanders bashes nonprofit hospitals over their tax breaks

In age of alternative facts, a scholarly course on calling out crap

Listen: Vivek Ramaswamy's star turn & leaky drug data

Walensky prepares to leave CDC — and Congress — behind

How the first Native Hawaiian psychiatrist helped diversify medicine

Trump demands the U.S. pay no more for drugs than other countries … again

Study: Spinal cord stimulation helps patients with paralysis walk again

hotspot

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Peter Marks talks Operation Warp Speed for Rare Diseases

Readout LOUD podcast: Merger Mondays, Ozempic panic

Akero's treatment for NASH falls short in cirrhosis study

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Trans patients at the end of life deserve respect and dignity

focus

focus

entertainment

knowledge